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Abstract
Purpose Reduced physical activity in many chronic diseases is consistently associated with increased morbidity. Little is 
known about physical activity in sarcoidosis. The aim of this study was to objectively assess physical activity in patients 
with pulmonary sarcoidosis and investigate its relationship with lung function, exercise capacity, symptom burden, and 
health status.
Methods Physical activity was assessed over one week in 15 patients with pulmonary sarcoidosis and 14 age-matched 
healthy controls with a tri-axial accelerometer (ActivPal™) and the International Physical Activity Questionnaire (IPAQ). 
All participants underwent pulmonary function tests, 6-min walk test (6MWT) and completed the Fatigue Assessment Scale 
(FAS), Medical Research Council (MRC) Dyspnoea Scale and the King’s Sarcoidosis Questionnaire (KSQ).
Results Patients with sarcoidosis had significantly lower daily step counts than healthy controls; mean (SD) 5624 (1875) 
versus 10,429 (2942) steps (p < 0.01) and a trend towards fewer sit-to-stand transitions each day (p = 0.095). Only two patients 
(13%) self-reported undertaking vigorous physical activity (IPAQ) compared to half of healthy individuals (p < 0.01). Daily 
step count was significantly associated with 6MWT distance in sarcoidosis (r = 0.634, p = 0.01), but not with forced vital 
capacity (r = 0.290), fatigue (r = 0.041), dyspnoea (r = −0.466) or KSQ health status (r = 0.099–0.484). Time spent upright 
was associated with fatigue (r = −0.630, p = 0.012) and health status (KSQ Lung scores r = 0.524, p = 0.045), and there was 
a significant correlation between the number of sit-to-stand transitions and MRC dyspnoea score (r = −0.527, p = 0.044).
Conclusion Physical activity is significantly reduced in sarcoidosis and is associated with reduced functional exercise capac-
ity (6MWD). Fatigue, exertional symptoms and health status were more closely associated with time spent upright and the 
number of bouts of physical activity, as compared to step counts. Further studies are warranted to identify the factors that 
determine different physical activity profiles in sarcoidosis.
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Introduction
Sarcoidosis is a multi-system disorder characterised by gran-
ulomatous inflammation. The lungs, skin, eyes and the mus-
culoskeletal system are frequently affected [1, 2]. Patients Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0040 8-019-00215 -6) contains 
supplementary material, which is available to authorized users.
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with sarcoidosis often present with dyspnoea, fatigue and 
arthralgia [3, 4]. The exercise capacity of patients with sar-
coidosis has been reported to be reduced, whether assessed 
with the 6-min walk test (6MWT) or cardiopulmonary exer-
cise test [3–6]. A limitation of measures exercise capacity is 
that they provide a limited insight into the impact the disease 
has on activities of daily living [7].
Physical activity is impaired in many chronic diseases and 
is associated with increased morbidity and mortality [8–11]. 
Physical activity can be assessed objectively with validated 
accelerometers for prolonged periods [12, 13]. Recent stud-
ies have reported that patients with chronic respiratory disor-
ders such as chronic obstructive pulmonary disease (COPD) 
[14–16] and idiopathic pulmonary fibrosis (IPF) [8, 9] have 
reduced physical activity. An important finding of these 
studies was that outcome measures of lung disease such as 
lung function, radiological imaging and health-related qual-
ity of life do not reflect the physical activity of patients [8, 
16, 17]. Bahmer et al. recently reported the clinical predic-
tors of walking physical activity (steps per day) in patients 
with mild sarcoidosis [18]. The step count was associated 
with exercise capacity but not with symptoms of physical 
fatigue [18]. This study, however, did not compare patients 
to a healthy control group and did not investigate the differ-
ent types of physical activity in daily life since this was not 
available with the physical activity monitor they used [18]. 
There are physical activity monitors available that can meas-
ure different types of activity. The ActivPal™, a piezoelec-
tric triaxial accelerometer, can assess daily step count, time 
spent in an upright posture, stepping time, and the number 
of sit-to-stand transitions. The reliability and validity of this 
monitor has been demonstrated in both healthy individuals 
and patients with COPD [19–22]. The monitor has good 
reliability for step counts and stepping cadence at different 
walking speeds in both indoor and outdoor environments 
and during motor vehicle travel with a measurement error 
of < 1% [19, 22].
In this pilot study, we aimed to investigate physical activ-
ity objectively with a triaxial accelerometer that can assess 
a range of activity in patients with sarcoidosis and healthy 
controls and investigate their relationships with exercise 
capacity, pulmonary function, fatigue and health status.
Methods
Participants and Clinical Characterisation
Consecutive participants with pulmonary sarcoidosis were 
recruited prospectively from a secondary care specialist 
clinic (King’s College Hospital, London, UK). The diag-
nosis of sarcoidosis and organ involvement were assessed 
by a multi-disciplinary team of clinicians and radiologists 
and established when clinical and histological features were 
consistent with those described in “A Case-Control Etio-
logic Study of Sarcoidosis” [23]. Chest radiographs were 
assessed by an experienced radiologist blinded to clinical 
details and reported according to the criteria described by 
Scadding [24]. Inclusion criteria were pulmonary involve-
ment and stable condition in the past 3 months as judged by 
the clinician. Exclusion criteria were the presence of respira-
tory conditions other than sarcoidosis, co-morbidities which 
were considered to affect daily activities (cardiac disease, 
peripheral vascular disease, stroke, central and peripheral 
nervous disease other than sarcoidosis, osteoarthritis), upper 
respiratory tract infection within the last 4 weeks, active 
psychiatric disorder and the use of walking aids.
Healthy controls were recruited prospectively through 
advertisement. The healthy control inclusion criteria were 
normal spirometry and exclusion criteria were identical to 
those of sarcoidosis subjects. Demographics, anthropo-
metric data and clinical characteristics were recorded. All 
participants gave informed written consent and the study 
was approved by the local research ethics committee (NRES 
Committee London Surrey Borders, 09/H0806/74).
Physical Activity Monitoring
Physical activity was assessed with the ActivPal™ (PAL 
Technologies Ltd, Glasgow, UK), a small, lightweight 
(35 × 53 × 7 mm, 15 g) piezoelectric triaxial accelerometer. 
The monitor was attached to participants’ upper thigh with 
hydrogel adhesion pads (PALstickies™, PAL Technologies 
Ltd, Galsgow, UK) and a Tegaderm™ transparent dressing 
(3M, St Paul, Minneapolis, USA). Accelerometry measure-
ments were made at a sampling rate of 15 Hz and summa-
rised into 15 s epochs, then downloaded and analysed using 
the manufacture’s software (ActivPal3™ version 7.1.18, 
PAL Technologies, Glasgow, UK).
Subjective Assessments
International Physical Activity Questionnaire
Participants were requested to complete the short version 
of the International Physical Activity Questionnaire (IPAQ) 
with the reference period being the last 7 days [25]. Craig 
et al. (2003) demonstrated that the IPAQ has acceptable reli-
ability and validity when compared against accelerometers 
[25]. The short IPAQ assesses the duration and frequency of 
moderate (4–8 metabolic equivalents (MET)) and vigorous 
(> 8 MET) physical activity and the time spent walking in 
the last 7 days [25]. Activity-specific scores were calculated 
as per scoring guidelines and were expressed as METs min-
utes per week and an overall weekly score. A higher score on 
the IPAQ indicates a higher level of physical activity [25].
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Fatigue Assessment Scale
The Fatigue Assessment Scale (FAS) is a validated tool to 
assess fatigue in participants with sarcoidosis [26, 27]. The 
FAS has 10 items and a score ranging from 10 to 50, where 
a score greater than 22 indicates fatigue [27].
MRC Dyspnoea Scale
Participants were asked to report the impact of breathless-
ness on their daily activities using the Medical Research 
Council (MRC) dyspnoea scale (score range 1–5) [28].
Health Status: King’s Sarcoidosis Questionnaire
The King’s Sarcoidosis Questionnaire (KSQ) was used to 
assess the health status of the participants with sarcoidosis 
[29]. The KSQ is a self-administered questionnaire which 
has been validated for use in subjects with sarcoidosis and 
has recently been utilised in clinical trials [29, 30]. The KSQ 
comprises of 29 questions which are divided into 5 modules: 
General Health (10 items), Lung (6 items), Skin (3 items), 
Eye (7 items) and Medications (3 items). The response to 
each item is recorded on a 7-point Likert scale. Partici-
pants completed the General Health and Lung modules and 
remaining modules as applicable. KSQ Scores range from 0 
to 100, where 0 is severe health status impairment and 100 
is no impairment [29].
Lung Function and Exercise Capacity
Spirometry was measured according to the Association for 
Respiratory Technology and Physiology and the European 
Respiratory Society guidelines (Jaeger MS-PFT Analyser 
Unit with Lab Manager Software version 5.32.0) [31, 32]. 
Participants underwent the 6-min walk test (6MWT) as per 
the European Respiratory Society (ERS) and American Tho-
racic Society (ATS) guidelines [33].
Protocol
Participants completed the questionnaires, spirometry and 
6MWT prior to the application of the activity monitor. Par-
ticipants were instructed to wear the activity monitor for 8 
consecutive days commencing on a Monday, removing it 
briefly only for personal hygiene. An illustrated manual with 
key information and guide for attaching the activity monitor 
and training was provided to participants. Participants were 
given a diary to record times spent sleeping and when the 
activity monitor was detached. Activity monitor data from 
the first and final day was excluded in the analysis since this 
included activity related to the study hospital visits. There-
fore, activity data from 6 days, which included 4 weekdays 
and 2 weekend days were analysed. When the activity moni-
tor was attached for < 8 h, data for that day were discarded.
Statistical Analysis
Data were analysed using Prism® Version 7.0c for macOS 
version 10.13.3 (GraphPad Software; San Diego, Califor-
nia, USA). The distribution of data was assessed using the 
D’Agostino and Pearson test. Parametric data were expressed 
as mean (standard deviation, SD) whereas non-parametric 
data were expressed as median (interquartile range, IQR). 
Parametrically distributed data were analysed with inde-
pendent unpaired Welch’s t tests to compare sample means, 
whereas comparison of non-parametric data was carried out 
using the Mann–Whitney U test. Chi-squared test was uti-
lised for categorical data. Correlations between variables 
were analysed with Pearson’s correlation coefficient (r) for 
parametric data and Spearman’s correlation coefficient (ρ) 
for non-parametric data. A p value of less than 0.05 was 
considered statistically significant.
A formal sample size was not calculated since this was 
a pilot study. A recent study investigating physical activity 
was able to detect significantly reduced physical activity in 
15 participants with fibrotic idiopathic interstitial pneumonia 
[8].
Results
Participant Characteristics
Fifteen consecutive participants with pulmonary sarcoidosis 
and fourteen healthy controls were recruited for this study. 
The demographics and clinical characteristics are shown 
in Table 1. Healthy controls were matched for age, gender 
and body mass index (BMI) (Table 1). One participant with 
sarcoidosis (active cardiac disease) and one healthy control 
 (FEV1 < 60% predicted) were excluded. A greater propor-
tion of participants with sarcoidosis were of black Afro-
Caribbean ethnicity compared to controls (Table 1). No 
participants had a clinical diagnosis of anxiety or depression.
Physical Activity Monitoring
Participants with sarcoidosis reported they were adherent 
with objective physical activity monitoring; only one partici-
pant (healthy control) reported non-adherence for more than 
8 h for 2 days. Data from these 2 days for this participant 
was not included in the analysis. Physical activity data are 
summarised in Fig. 1.
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Table 1  Demographic and clinical characteristics of the study partici-
pants
Data presented as mean  (SD) or absolute number (%). Immunosup-
pressants were those prescribed at the time of the study
BMI body mass index; MRC Medical Research Council; ACE angi-
otensin-converting enzyme; FEV1 forced expiratory volume in 1  s; 
FVC forced vital capacity; TLCO diffusion capacity of lung for carbon 
Healthy controls 
(n = 14)
Sarcoidosis (n = 15)
Age (years) 46.5 (5.5) 52.7 (15.5)
Female (n, %) 10 (71) 11 (73)
BMI (kg/m 2) 27.1 (4.1) 27.7 (4.4)
Ethnicity (n, %)
 Caucasian 10 (71) 3 (20)
 Afro-Caribbean 1 (7) 9 (60)
 Other 3 (21) 3 (20)
Smoking status (n, %)
 Current 0 (0) 1 (7)
 Ex-smoker 4 (29) 4 (27)
 Never 10 (71) 10 (67)
Time since diagnosis (years) 8.3 (8.4)
Organ involvement N/A
 Lungs 15 (100)
 Skin 6 (40)
 Eyes 3 (20)
 Other 8 (53)
Multiple organ involvement N/A
 ≥2 12 (80)
 ≥3 5 (33)
Scadding stage N/A
 0 0 (0)
 1 4 (27)
 2 3 (20)
 3 4 (27)
 4 4 (27)
Pulmonary function
 FEV1% predicted 98.1 (14.7) 65.7 (18.6)*
 FVC% predicted 107.3 (17.0) 78.5 (17.7)*
 FEV1/FVC 75.9 (6.1) 69.1 (12.6)*
 TLCO% predicted 86.8 (7.0) 58.4 (13.8)*
ACE (IU/L) N/A 54 (28)
Immunosuppressant N/A
 None 5 (33)
 Prednisolone 10 (67)
 Methotrexate 3 (20)
 Azathioprine 1 (7)
 Hydroxychloroquine 2 (14)
 Inhaled corticosteroid 2 (14)
MRC dyspnoea score 1 (1) 3 (1)
FAS 15 (4) 23 (7)
KSQ N/A
 General Health 55 (20)
 Lung 60 (19)
 Medication 68 (33)
 General Health + Lung 57 (20)
monoxide; FAS Fatigue Assessment Scale; KSQ King’s Sarcoidosis 
Questionnaire
*p < 0.05
Table 1  (continued)
Fig. 1  Physical activity in participants with sarcoidosis and healthy 
controls
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Fig. 2  A comparison of physical activity (steps) between participants 
with sarcoidosis and healthy controls on a daily step counts and b 
daily stepping time
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Step Count and Stepping Time
Daily step counts were significantly lower in participants 
with sarcoidosis as compared to healthy controls; mean 
(SD) 5624 (1875) versus 10,429 (29,422) steps, respectively, 
mean difference (95% CI) 4804 (2888–6720) steps, p < 0.001 
(Fig. 2a; Table 2). Daily stepping time was also signifi-
cantly lower in participants with sarcoidosis than in healthy 
controls; mean (SD) 1.18 (0.35) versus 1.97 (0.46) h/day, 
respectively, mean difference (95% CI) 0.78 (0.47–1.10), 
p < 0.001 (Fig. 2b; Table 2).
Sit‑to‑Stand Transitions and Standing Time
There was a trend towards a lower number of sit-to-stand 
transitions in participants with sarcoidosis than in healthy 
controls; median (IQR) 53.0 (35.0–59.0) versus 62.5 
(46.8–68.8) transitions/day, respectively, p = 0.095. There 
was no significant difference in the time spent standing 
between participants with sarcoidosis and healthy controls; 
median (IQR) of 4.16 (2.86–6.27) versus 3.77 (3.48–4.60) 
h/day respectively, p = 0.915 (Table 2).
Association Between Physical Activity and Clinical 
Characteristics
There was no significant association between mean daily 
step count and age (r = − 0.43, p = 0.107), BMI (r = 0.06, 
p = 0.842), Scadding Chest X-ray staging (ρ = − 0.35, 
p = 0.202), number of organs involved (ρ = 0.23, p = 0.410) 
or use of corticosteroids (p = 0.17). There was a trend 
towards an association between number of organs involved 
and daily standing time (ρ = − 0.47, p = 0.082).
Exercise Capacity (6MWT)
The 6-min walking distance (6MWD) was significantly 
lower in participants with sarcoidosis compared to healthy 
controls; mean (SD) 375 (59) versus 487 (92) metres; mean 
difference (95% CI) 112 (52, 172) metres, p < 0.001 (Fig. 3). 
There was a significant correlation between 6MWD and the 
Table 2  Objective and 
subjective assessments of 
physical activity in participants 
with sarcoidosis and healthy 
controls
Data presented as mean (SD) or median (IQR)
6MWD 6-min walk distance; IPAQ International Physical Activity Questionnaire; MET metabolic equiva-
lent
*p = 0.0009
† p < 0.0001
‡ p = 0.017
Healthy controls (n = 14) Sarcoidosis (n = 15)
Objective assessments
 6MWD (m) 487 (92) 375 (59)*
Physical activity
 Step counts (/day) 10,429 (2942) 5624 (1875)†
 Sit to stand transitions (/day) 63 (47–69) 53 (35–59)
 Upright time (h/day) 5.69 (5.26–6.47) 5.71 (3.73–7.56)
  Stepping time (h/day) 1.86 (1.73–2.23) 1.17 (0.99–1.55)†
  Standing time (h/day) 3.77 (3.48–4.60) 4.16 (2.86–6.27)
Subjective assessments
 IPAQ scores
  Overall (MET-min/week) 3230 (1912–5599) 2153 (1152–4925)
  Walking (MET-min/week) 1287 (412–1914) 1386 (330–3366)
  Moderate PA (MET-min/week) 840 (210–1510) 320 (127–2175)
  Vigorous PA (MET-min/week) 480 (0–3360) 0 (0–0)‡
Sarcoidosis Healthy controls
0
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p=0.0009
Fig. 3  A comparison of exercise capacity between participants with 
sarcoidosis and healthy controls
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daily step count in participants with sarcoidosis (r = 0.63, 
p = 0.011; Fig. E1). There was a significant association 
between 6MWD and self-reported vigorous activity on IPAQ 
(ρ = 0.52, p = 0.048) and a trend to significance for the rela-
tionship between 6MWD and self-reported walking activ-
ity on IPAQ (ρ = 0.48, p = 0.071). There was no significant 
correlation between 6MWD and self-reported total physical 
activity on IPAQ (ρ = 0.06, p = 0.829).
Lung Function
There was no association between daily step count and 
lung function measures in participants with sarcoidosis 
 (FEV1: r = 0.27, p = 0.330; FVC: r = 0.29, p = 0.294;  TLCO: 
r = − 0.01, p = 0.963). This was in contrast to healthy partici-
pants in which there were significant relationships  (FEV1: 
r = 0.71, p = 0.007; FVC: r = 0.69, p = 0.009; TLCO: r = 0.80, 
p = 0.001). There was no significant association between 
lung function measures and daily stepping time in partici-
pants with sarcoidosis  (FEV1: r = 0.17; FVC: r = 0.30;  TLCO: 
r = − 0.11), daily standing time  (FEV1: r = − 0.02; FVC: 
r = − 0.18; TLCO: r = − 0.31) or daily sit to stand transitions 
 (FEV1: r = − 0.17; FVC: r = − 0.05;  TLCO: r = − 0.03), all 
p > 0.05.
Subjective Assessments
International Physical Activity Questionnaire
Vigorous physical activity was significantly lower in par-
ticipants with sarcoidosis than in healthy controls; median 
(IQR) of 0 (0) versus 480 (0–3360) MET-min/week, respec-
tively, p = 0.017 (Table 2). The majority of participants 
with sarcoidosis, 13 (87%), reported no vigorous activity in 
contrast to 7 (50%) healthy controls (p < 0.01). Participants 
with sarcoidosis reported lower overall physical activity 
compared to healthy controls but this was not statistically 
significantly different; median (IQR) 2153 (1152–4925) 
versus 3230 (1912–5599) MET-min/week, respectively, 
p = 0.326 (Table 2).
In participants with sarcoidosis, there was a significant 
association between walking activity on IPAQ and daily 
stepping time (ρ = 0.61, p = 0.018). There was a trend to 
significance for the relationship between walking activity 
(IPAQ) and daily step count (ρ = 0.52, p = 0.052). There was 
no association between IPAQ total score and objective daily 
step count (ρ = 0.16, p = 0.594).
Fatigue: Fatigue Assessment Scale
Participants with sarcoidosis reported more fatigue than 
healthy controls; mean (SD) FAS score 23.27 (6.70) versus 
15.43 (3.65); mean difference (95% CI) 7.84 (3.72–11.96), 
p < 0.001 (Table E1). There was a significant relationship 
between fatigue (FAS) in sarcoidosis and the time spent 
upright per day measured with the accelerometer (r = − 0.63, 
p = 0.013) and time spent standing per day (r = − 0.67, 
p = 0.006; Fig. E2a). There was no significant association 
between fatigue and sit to stand transitions in participants 
with sarcoidosis (r = − 0.01, p = 0.973) or daily step counts 
(r = 0.04, p = 0.884). Fatigue was not associated with self-
reported overall IPAQ physical activity (ρ = 0.28, p = 0.325) 
in participants with sarcoidosis (Table E1). For healthy con-
trols, there was no significant correlation between fatigue 
and objective assessments of physical activity (ρ = − 0.03 
to 0.15, all p > 0.05).
MRC Dyspnoea
Participants with sarcoidosis reported mean (SD) MRC 
dyspnoea score 3.0 (1). There was a significant correlation 
between MRC dyspnoea scores and the number of sit to 
stand transitions (r = − 0.53, p = 0.044). There was also a 
trend towards significance in the relationship between the 
MRC dyspnoea scores and daily step counts in participants 
with sarcoidosis (r = − 0.47, p = 0.080).
Health Status: King’s Sarcoidosis Questionnaire
The health status of the participants with sarcoidosis meas-
ured with the KSQ was moderate to severely impaired 
(Table  1). There were significant correlations between 
the KSQ Lung scores and time spent standing per day 
(r = 0.58, p = 0.023; Fig. E2b) and time spent upright 
(r = 0.52, p = 0.045). There was no significant association 
between KSQ Lung scores and daily step count (p = 0.484), 
daily stepping time (p = 0.611) and sit to stand transitions 
(p = 0.850). There was no significant correlation between 
KSQ General Health scores and objective measures of physi-
cal activity (r = − 0.38 to 0.42, p = 0.115–0.262). There was 
a significant association between the self-reported overall 
physical activity (IPAQ scores) and the KSQ lung domain 
(ρ = − 0.56, p = 0.042; Table E1).
Discussion
This is the first study to objectively assess physical activ-
ity in sarcoidosis with a validated triaxial accelerometer 
[19–22]. Physical activity was significantly reduced in 
patients with sarcoidosis compared to healthy controls. The 
6-min walk test had the strongest association with physi-
cal activity in patients with sarcoidosis. Surprisingly, there 
was no significant association between daily step counts and 
fatigue. Fatigue was, however, associated with reduced time 
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spent upright. There was no association between lung func-
tion measures and physical activity in sarcoidosis.
We investigated different types of physical activity in 
sarcoidosis made possible by utilising a triaxial accelerom-
eter [19–22]. Daily step counts and daily stepping time were 
reduced in patients with sarcoidosis compared with healthy 
controls. Participants with sarcoidosis spent less time walk-
ing and had a lower cadence (steps/minute) compared to 
healthy controls. Self-reported physical activity was lower 
in patients with sarcoidosis compared with healthy controls, 
but the difference was not statistically significant. Self-
assessed physical activity is known to correlate poorly with 
objective measures [34]. Self-reported vigorous physical 
activity was, however, significantly reduced in patients with 
sarcoidosis. Furthermore, objective daily step counts corre-
lated better with self-reported IPAQ walking activity com-
pared to IPAQ overall activity which reflects a wide range of 
daily activities, many of which do not involve walking. The 
6MWT had the strongest association with physical activity 
of all clinical outcome measures assessed, similar to find-
ings in patients with interstitial lung disease and sarcoidosis 
[8, 9, 18]. The correlation between 6MWD and physical 
activity was moderate, suggesting that measures of exercise 
capacity do not fully capture physical activity. There was a 
trend towards an association between dyspnoea and daily 
step counts and sit-to-stand transitions. There was, however, 
no association between daily step counts and lung function 
or health-related quality of life. Health-related quality of life 
and dyspnoea were, however, associated with reduced time 
spent upright.
Fatigue is a common and troublesome symptom of sar-
coidosis [6, 35, 36]. We found no association between daily 
step counts and fatigue, consistent with the findings of 
Bahmer et al. [18]. However, fatigue was associated with 
reduced time spent upright, and therefore, the impact of 
fatigue may be limited to specific types of physical activity. 
The reason for reduced physical activity in sarcoidosis is 
unclear. Physical activity parameters were not related to age, 
BMI, disease severity or medication use. The lack of clear 
associations with individual factors suggests that there may 
be multi-factorial reasons for reduced physical activity. The 
factors potentially relevant include cardiac function, psy-
chological and medications [17, 37, 38]. The mechanisms 
of reduced physical activity in sarcoidosis should be studied 
further.
There are some limitations to our study. We investigated a 
small number of patients, and therefore, our findings need to 
be replicated in a larger study. Physical activity was assessed 
over 1 week, and this interval may have been too short to be 
representative of habitual physical activity. Some patients 
were taking treatments such as corticosteroids though it 
has been demonstrated that the use of corticosteroids does 
not affect muscle strength [4]. We did not find a significant 
difference in physical activity between those patients taking 
corticosteroids and no medications. There were differences 
in ethnicity between patients and healthy controls which may 
have biased our results. Our sample size was too small to 
analyse for any differences between ethnic groups. We did 
not assess the level of education and occupation of subjects 
and its impact on activity. Marshall et al. demonstrated that 
social class moderates the relationship between ethnicity and 
physical activity, and suggested that a focus on ethnicity in 
physical activity detracts from the significant role played by 
social classes [39]. It is possible that the control group may 
have been motivated to participate in an activity study and, 
therefore, were physically fit. Future studies using a matched 
case–control design can overcome this potential bias.
In conclusion, physical activity is reduced in patients with 
sarcoidosis compared with healthy controls. The assessment 
of physical activity was well tolerated. Physical activity 
monitors can provide a unique assessment of the impact of 
disease on function that is not captured by existing clini-
cal outcome measures for sarcoidosis, and can potentially 
be used to assess response to therapy. The mechanism for 
reduced physical activity in sarcoidosis is unclear but is 
likely to be multi-factorial and needs further study.
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